Fewer needles, same accuracy? new prostate biopsy study aims to reduce harm
NCT ID NCT05998278
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study compares a personalized biopsy method that uses fewer needle cores to the standard approach for diagnosing prostate cancer. Researchers will enroll 330 men with suspected prostate cancer and randomly assign them to either the personalized or standard biopsy. The goal is to see if the new method maintains high cancer detection while causing fewer complications like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Urology, Fujian Union Hospital, Fujian Medical University
RECRUITINGFuzhou, Fujian, 350000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Personalized optimization of systematic prostate biopsy (procedure)
What this could lead to
If successful, this could offer a safer, more accurate biopsy method for prostate cancer detection, reducing bleeding and infection risks.
What could go wrong
This is a relatively small, early-stage study. The model may not perform as well in broader populations, and reducing cores could miss some cancers.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.